TXG (10x Genomics) Ending Cash Position: $490.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TXG 10x Genomics Inc TXG
58 GF Score
Price $52.15
GF Value $18.83
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is 10x Genomics Ending Cash Position?

10x Genomics TXG +14.10% 58 Ending Cash Position is $490.3 Mil as of Mar. 2026. GuruFocus rates TXG with a GF Score™ of 58/100 and a GF Value™ of $18.83 (Significantly Overvalued). The stock has 8 warning signs investors should review.

10x Genomics's Ending Cash Position for the quarter that ended in Mar. 2026 was $490.3 Mil.

10x Genomics's quarterly Ending Cash Position increased from Sep. 2025 ($432.7 Mil) to Dec. 2025 ($474.0 Mil) and increased from Dec. 2025 ($474.0 Mil) to Mar. 2026 ($490.3 Mil).

10x Genomics's annual Ending Cash Position declined from Dec. 2023 ($359.3 Mil) to Dec. 2024 ($344.1 Mil) but then increased from Dec. 2024 ($344.1 Mil) to Dec. 2025 ($474.0 Mil).

10x Genomics Ending Cash Position Related Terms

10x Genomics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for 10x Genomics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics Ending Cash Position Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 596.07 227.35 359.28 344.07 473.97

10x Genomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 397.71 432.71 473.97 490.29 0.00
TXG
58GF Score
10x Genomics Inc TXG
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

10x Genomics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

10x Genomics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=344.067+129.899
=474.0

10x Genomics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=473.966+16.319
=490.3

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $490.3 Mil mean?
10x Genomics (TXG) has a Ending Cash Position of $490.3 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on 10x Genomics and its competitors.
Is 10x Genomics' Ending Cash Position too high?
10x Genomics' current Ending Cash Position is $490.3 Mil. Overall, 10x Genomics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Ending Cash Position compare to HNGE and WAY?
10x Genomics' Ending Cash Position of $490.3 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on 10x Genomics and its competitors. 10x Genomics's current Ending Cash Position is $490.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.83, compared to a current price of $52.15 — trading 177% above its estimated fair value. The current Ending Cash Position is $490.3 Mil. 10x Genomics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For 10x Genomics (TXG), the current Ending Cash Position is $490.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 10x Genomics (TXG) Overvalued in 2026?

Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued. The current stock price of $52.15 is trading 177% above its estimated GF Value™ of $18.83. GuruFocus considers 10x Genomics to be Significantly Overvalued.

Key valuation signals for TXG:

  • Ending Cash Position: $490.3 Mil
  • GF Value™: $18.83 vs. price of $52.15 (177% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

10x Genomics Business Description

Other Exchanges 0A88:UK1KJ:Germany
Address 6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
58GF Score

Get the complete analysis for TXG

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$52.15
Price
$18.83
GF Value